August 19, 2021
MEI Pharma and Kyowa Kirin said on August 17 that the first patient has been dosed in a global PIII study for their oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor zandelisib for the treatment of certain forms of lymphomas. The randomized,...read more